Original Article

The influence of zoledronate and teriparatide on gamma delta T cells in mice

Eiki Yamachika a*, Yuichi Matsui a, Masakazu Matsubara b, Tatsushi Matsumura b, Naoki Nakata b, Norifumi Moritani b, Atsushi Ikeda a, Hidetsugu Tsujigiwa c, Naoya Ohara d, Seiji Iida b

a Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Hospital, 2-5-1 Shikata-cho, Kitaku, Okayama 7008558, Japan
b Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-Cho, Kitaku, Okayama 7008558, Japan
c Department of Life Science, Faculty of Science, Okayama University of Science, 1-1 Ridaicho, Kitaku, Okayama 7000005, Japan
d Department of Oral Microbiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-Cho, Kitaku, Okayama 7008558, Japan

Received 2 December 2016; Final revision received 23 February 2017
Available online 24 April 2017

KEYWORDS
bisphosphonate; BRONJ; zoledronate; teriparatide; gamma delta T cell

Abstract  Background/purpose: Few studies have investigated the possibility that bisphosphonate-related osteonecrosis of the jaw (BRONJ) might reflect an immune response; however, gamma delta T cells have been shown to significantly decline in the blood of BRONJ patients. Additionally, there have been some reports of teriparatide usage for the treatment of BRONJ. In this study, we compared the effects of zoledronate and teriparatide on lymphocyte populations and inflammatory cytokine production in mice.

Materials and methods: Thirty female ICR mice were divided into three groups (n = 10 each): a vehicle, a zoledronate, and a teriparatide group. Drugs were administered for 8 weeks in each group. Lymphocytes in the blood and thymus were analyzed and femurs were used for histological observation and lymphocytes analysis of bone marrow. Cytokines were measured in separated serum using Milliplex® multiplex immunoassay analysis.

Results: Zoledronate decreased the T cell number in the bone marrow. Additionally, serum levels of interleukin (IL)-2, IL-7, IL-12, IL-15 and RANTES, which are cytokines that affect T cell activation, differentiation and/or proliferation, were significantly lower in zoledronate treated mice. Conversely, teriparatide treatment induced an increase in gamma delta T cells in peripheral blood.

* Corresponding author. Fax: +81 862356699.
E-mail address: eikiyama@md.okayama-u.ac.jp (E. Yamachika).

http://dx.doi.org/10.1016/j.jds.2017.03.007
1991-7902 © 2017 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Conclusion: Gamma delta T cells in the bone marrow are expected to decrease with zoledronic acid treatment and increase with teriparatide treatment. If BRONJ involves a loss of gamma delta T cells in the circulation or bone marrow, then the increase in gamma delta T cells that is induced by teriparatide may account for its ability to resolve BRONJ.

© 2017 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Nitrogen-containing bisphosphonates (NBPs), which are synthetic analogs of pyrophosphate, are an effective treatment for osteoporosis, hypercalcemia of malignancy, osteolytic lesions in multiple myeloma, and bone metastases from solid tumors, including breast cancer and hormone-independent prostate cancer.1,2 NBPs have a high affinity for bone minerals3 and accumulate in high concentrations in bones.4 They are selectively taken up by osteoclasts and strongly inhibit bone resorption by inducing apoptosis in osteoclasts.5 However, serious side effects such as bisphosphonate-related osteonecrosis of the jaw (BRONJ) have been reported with the use of NBPs.6 BRONJ appears as a painful lesion of exposed necrotic bone in the mandible or maxilla that fails to heal within 8 weeks.7 It has been reported that BRONJ is limited to the jaw bone and is not observed in other bones. The cause of BRONJ is poorly understood, but NBPs have been shown to reduce bone remodeling6 and angiogenesis,7 and thus the suppression of bone turnover and jaw angiogenesis resulting from NBPs has been proposed as the underlying mechanism of BRONJ.

BRONJ is thought to be an inflammation process. Although innate immunity has a critical role in this inflammation process, few studies have investigated the possibility that BRONJ might reflect an immune response. For example, lymphocytes are potent inducers of immune responses, but few studies have been carried out to understand the association between BRONJ and lymphocytes. However, in 2013, an intriguing association between loss of γδ T cells, following NBP therapy and development of BRONJ was reported.10 In that study, six immunocompromised patients, who further underwent a significant loss of γδ T cells following NBP therapy, all experienced BRONJ. Conversely, Kunzmann reported that γδ T cells were activated by NBPs11 with a consequent release of cytokines such as interferon γ (IFN-γ), which might contribute to the acute-phase reaction that is commonly observed following the first infusion of a NBP.

Apart from NBPs, there are some other types of anti-osteoporosis drugs, one of which is Teriparatide (recombinant human parathyroid hormone-(1-34) (PTH)-(1-34)). PTH is the major hormone that regulates bone remodeling. Although continuous infusion of high doses of PTH has catabolic effects, intermittent administration of PTH (iPTH) at low doses is anabolic for bone formation. Teriparatide is an anabolic agent that has been shown to increase both bone mass and bone strength.12 The PTH receptor (PPR) is mainly expressed in the bone and kidney. In the bone, PPR is expressed in osteoclasts13 but is mainly expressed in cells of osteoblastic lineage such as osteocytes.14 Osteocytes are necessary for iPTH anabolic effects.14 Treatment with iPTH activates the Wnt signaling pathway in osteoblasts by suppressing sclerostin production by osteocytes.15–20 The PPR is also expressed by T cells,21 and these cells are required for iPTH to exert its bone anabolic effect.21–23 The bone anabolic response to iPTH is blunted in the absence of T cells and is restored by adoptive transfer of these cells.21,22 T cells mediate the iPTH anabolic effect on bone through the upregulation of Wnt10b on their surface.22 Wnt10b interacts with osteoblasts, thereby upregulating Wnt pathway signaling and inducing bone formation.

The above findings indicate that these two anti-osteoporosis drugs have different mechanisms for modulation of bone metabolism and the immune system. Interestingly, there have also been some reports of teriparatide use in the treatment of BRONJ.24–26

Based on the above findings, we hypothesized that NBPs would induce immune alteration. We further hypothesized that this alteration might be associated with lymphocytes including γδ T cells, and that teriparatide might also have some effects on the immune system.

Therefore, in this study, we analyzed lymphocyte populations, including γδ T cells, in mice treated with zoledronate (a NBP) or teriparatide, and we determined the effects of zoledronate and teriparatide on inflammatory cytokine production.

Materials and methods

Ethics statement

The animal study was approved by the Animal Ethical Committee of Okayama University. All experiments in this study regarding the use of laboratory animals were performed in accordance with the guidelines of Okayama University.

Reagents

Zoledronate was purchased from Santa Cruz Biotechnology (Dallas, TX) and teriparatide was purchased from Bachem AG (Bubendorf, Switzerland).

Mice

Thirty female ICR mice at 12 weeks of age were obtained from CLEA Japan (Tokyo, Japan) and were divided into three
groups (n = 10 each): vehicle group, zoledronate group, and teriparatide group. In the vehicle group, physiological saline was administered intraperitoneally. In the zoledronate group, zoledronate was administered intraperitoneally. The dose of zoledronate was set at 200 \(\mu\)g/Kg/day and 3 days/week. In the teriparatide group, teriparatide was administered intraperitoneally. The dose of teriparatide was set at 40 \(\mu\)g/Kg/day and 5 days/week. Mice were housed under standard conditions and food and water were available \textit{ad libitum}. The doses used were the minimal dose at which effects were confirmed in the preliminary study. Drugs were administered for 8 weeks in each group. This administration period was also confirmed in the preliminary study. At the end of the administration period, ether anesthesia was induced and blood was collected from the caudal vena cava. The thymus and the femurs were then collected for lymphocyte and bone analysis.

**Histological observation**

In each group, the right femur was collected from mice and was immediately fixed in 4% phosphate-buffered formaldehyde solution for 24 h. Fixed tissues were demineralized using 10% ethylenediaminetetraacetic acid for 30 days, dehydrated in the conventional manner and embedded in paraffin. Sections (5 \(\mu\)m-thick) were stained with hematoxylin and eosin (HE) and immunohistochemical staining was performed using an anti-mouse CD3 antibody (ab5690 Abcam Ltd., Cambridge, UK).

**Flow cytometry**

Flow cytometric studies were performed on blood and thymus using a FACSAria (BD Franklin Lake, NJ). The cells were labeled with fluorescein isothiocyanate-, phycoerythrin-cyanine-7-, allophycocyanin-, phycoerythrin-, brilliant violet 421-, allophycocyanin-, phycoerythrin-anti-mouse CD45 (BioLegend, San Diego, CA), CD3e (BioLegend), CD19 (eBioscience, San Diego, CA), CD49b (eBioscience), CD4 (eBioscience), CD8a (BioLegend), and TCR\(\gamma/\delta\) (BioLegend), respectively. Data analysis was conducted using FlowJo version 7.5 software (Tree Star, Inc., Ashland, OR).

**Biochemical analysis of mouse serum samples**

Blood samples were centrifuged in the conventional manner to separate serum. A total of 32 cytokines were then measured in this serum using the Milliplex\textsuperscript{TM} multiplex immunoassay analysis (Merck Millipore Darmstadt, Germany).

**Statistical analysis**

Unless otherwise stated, all values are presented as means \(\pm\) SD of measurements from three independent experiments. Data were analyzed by one-way ANOVA for multiple group comparison. Tukey’s HSD test was used to specify differences between groups. A \(p\)-value of less than 0.05 was considered significant.

**Results**

**CD3\(^+\) cells in the femur bone marrow**

We first analyzed expression of the pan T cell marker CD3 in the bone marrow of the femurs of the three mouse groups of vehicle (Fig. 1a), zoledronate (Fig. 1b) and teriparatide

*Figure 1* Analysis of T (CD3\(^+\)) cells in the bone marrow of treated mice. (a–c). Immunohistochemical staining of CD3\(^+\) cells in the three mouse groups. Paraffin sections of bone marrow from the vehicle (a), zoledronate (b) and teriparatide (c) mouse groups were immunohistochemically stained for CD3\(^+\) cells (= T cells). (Scale bar = 20 \(\mu\)m). There appeared to be fewer CD3\(^+\) cells in the zoledronate group than in the other two groups. Arrows point to CD3\(^+\) cells. (d). Quantification of the CD3\(^+\) cell number in Fig. 1a–c. The Y-axis shows the number of CD3\(^+\) cells in every 100 \(\mu\)m square of bone marrow. The X-axis shows the vehicle group, the zoledronate group (Zole) and the teriparatide group (Teri). Data are expressed as the mean cell numbers of each group. Bars represent the standard deviation. The cell number in the zoledronate group was significantly different from that of the vehicle group and the teriparatide group. (*\(P < 0.05\); Tukey’s HSD test).
(Fig. 1c) treatment. Immunohistochemical staining suggested that zoledronate reduced the number of CD3+ cells in the bone marrow.

CD3+ cell numbers in the stained tissues were then counted and are shown in Fig. 1d. The mean number of CD3+ cells in every 100 µm square of bone marrow was 2.5, 0.25 and 1.5 in the vehicle, zoledronate and teriparatide groups, respectively. These results showed that zoledronate significantly reduced T cell number in the mouse bone marrow compared to the other two groups.

Flow cytometric analysis

Cells obtained from blood were then analyzed using flow cytometric analysis for the expression of cell surface markers. T cells were defined as CD45+/CD19-/CD3+ cells. B cells were defined as CD45+/CD19+ cells. Double-positive (DP) T cells were defined as CD45+/CD19-/CD3+ /CD4+ /CD8+ cells. Double-negative (DN) T cells were defined as CD45+/CD3+ /CD4-/CD8-cells. \( \gamma \delta \) T cells were defined as CD45+/CD3+ /CD4-/CD8-/TCR\( \gamma \delta \)+ cells.

Analysis of blood cells

The percentage of T cells in the total blood lymphocytes was 43%, 43% and 32% in the vehicle group, the zoledronate group and the teriparatide group, respectively. Administration of zoledronate induced neither an increase nor a decrease in the T cell population in blood compared to the control. However, the T cell population was significantly lower in the teriparatide group than in the other two groups (Fig. 2a).

The percentage of B cells in the total blood lymphocytes was 43%, 43% and 57% in the vehicle group, the zoledronate group and the teriparatide group respectively. The percentage of B cells in the teriparatide group was significantly higher than that in the vehicle and zoledronate groups (Fig. 2b).

The percentage of \( \gamma \delta \) T cells in the total blood lymphocytes was 2.1%, 2.4% and 4.4% in the vehicle group, the zoledronate group and the teriparatide group respectively. Administration of zoledronate did not induce any increase or decrease in the \( \gamma \delta \) T cell population in blood. However, the \( \gamma \delta \) T cell population in blood was significantly higher in the teriparatide group than in the other two groups (Fig. 2c).

Thus, zoledronate treatment had no influence on T cell, B cell or \( \gamma \delta \) T cell populations in blood; however, teriparatide treatment decreased the T cell population and increased the B cell and \( \gamma \delta \) T populations in blood compared to the other two groups.

Analysis of thymus cells

We next analyzed the percentage of DP T cells, DN T cells, SP T cells and \( \gamma \delta \) T cells in thymus T cells. The percentage of DP cells was 16%, 13% and 36% in the vehicle group, the zoledronate group and the teriparatide group, respectively (Fig. 2d); the percentage of DN cells was 1.5%, 1.8% and 2.3%, respectively (Fig. 2e), that of SP cells was 83%, 86%.
and 61%, respectively (Fig. 2f) and that of γ0 T cells was 0.5%, 0.4% and 0.6%, respectively (Fig. 2g).

Administration of zoledronate induced no increase or decrease in DP, DN or SP T cell populations in the thymus compared to the control. However, in the teriparatide group, the percentage of the DP and DN T cell populations was significantly higher than that of the other two groups and the percentage of the SP T cell population was significantly lower than that of the other two groups. Since the number of γ0 T cells in the thymus was very small, it was not possible to detect significant differences in γ0 T cells in the thymus among these 3 groups. In summary, teriparatide increased DP T cells and the DN T cell population and decreased the SP cell population in the thymus.

The immunohistochemical stainings of femur bone marrow and these flow cytometric analyses showed that zoledronate decreased T cells in the bone marrow but did not influence T cell, γ0 T cell or B cell populations in the blood. However, teriparatide decreased the T cell population and increased the γ0 T cell and B cell populations in blood. In thymus cells, zoledronate had no influence on DP T cell-, DN T cell- or SP T cell-populations; however, teriparatide increased DP T cell- and DN T cell-, and decreased SP T cell-populations.

Biochemical analysis of mouse serum samples

The levels of serum cytokines were measured after the 8-week administration period of vehicle, zoledronate or teriparatide to mice. The levels of IL-2, IL-7, IL-12, IL-15, RANTES(CCL-5) and tumor necrosis factor (TNF)α were significantly lower in the zoledronate group than in the vehicle group or the teriparatide group (Fig. 3).

Discussion

Bone and the immune system are frequently discussed together and numerous studies have been performed under the understanding that bone disease and immunology are linked. For example, T and B cells are now implicated in the pathological bone loss associated with a variety of conditions, including ovariectomy-induced bone loss, hyperparathyroidism, periodontal infection, and rheumatoid arthritis (RA). Regarding T cells, promotion of T cell activation ultimately leads to receptor activator of nuclear factor kappa-B ligand (RANKL) and TNFα secretion.

However, few studies have been undertaken to determine the association between NBP exposure and immune cells, and no study has been performed to investigate the effect of teriparatide as a treatment for BRONJ viewed from the standpoint of immune cells.

Recently, γ0 T cells have been discussed in association with NBP exposure and two different types of results were reported; one result was that NBPs decreased γ0 T cells in human BRONJ patients and the second result was that NBPs activated γ0 T cells in acute-phase reaction patients. The antigenic specificity of individual T cells is achieved through a heterodimeric complex that is comprised of two receptor chains and is referred to as the T cell receptor (TCR). Complexes that are comprised of a heterodimerized α and β chain are the most common TCRs and T cells bearing these complexes are referred to as αβ T cells. However, γ0 T cells express TCRs that are comprised...
of a γ chain paired with a δ chain. γδ T cells are functionally distinct from αβ T cells and their TCR-specificity is directed almost exclusively towards nonpeptide antigens.

Regarding intermittent parathyroid hormone (iPTH) administration and T cells, the anabolic actions of iPTH are achieved through the induction of Wnt10b in T cells. This induction leads to osteoblast proliferation and differentiation, and activation of quiescent lining osteoblasts. Osteoblast life-span is increased by suppression of apoptosis and down-modulation of the Wnt receptor antagonist sclerostin that is produced by osteocytes. 21,22,32

Our results showed that neither the proportion of CD3+ T cells nor the proportion of γδ T cells in mouse blood changed with zoledronate treatment. These results appear to differ from the reported loss of Vγ9Vδ2 T cells following NBP therapy and development of BRONJ, 10 or from the report that Vγ9Vδ2 T cells are activated by NBP in the case of an acute-phase reaction. 11 However in our case, although the mice were treated with zoledronate, these mice did not have any necrotic bone, they were not diagnosed as BRONJ, and their conditions were not those of an acute-phase reaction situation. Additionally, the immune system of the mouse and the human are not exactly the same and therefore a direct comparison may not be possible. The cytokine analyses indicated that zoledronate reduced the serum levels of IL-2, IL-7, IL-12, IL-15 and RANTES. These cytokines have effects on T cell activation, differentiation and proliferation. 33,34 These results regarding the effects of zoledronate on T cell-related cytokines are consistent with the loss of T cells in the bone marrow that was observed following zoledronate treatment. Moreover, TNFα levels were decreased by zoledronate treatment, suggesting that zoledronate inhibited TNFα secretion by reducing T cell activation. This loss of TNFα suggests the inhibition of osteoclast activation that is believed to be the pharmacological effect of NBP.

In addition, our results also showed that teriparatide (iPTH) treatment resulted in an increase in the γδ cell population in blood. In the thymus, teriparatide increased DP and DN T cells and decreased SP T cells. Because DN T cells are precursors of γδ T cells, the increase in DN T cells in the thymus as a result of teriparatide exposure might suggest that these DN T cells differentiate into γδ T cells and are linked to the increased number of γδ cells in the blood of teriparatide-treated mice. To our knowledge, this is the first report of analysis of γδ cell populations following NBP and teriparatide treatment of mice.

Furthermore, if BRONJ is related to a loss of γδ T cells in the circulation, the increase in γδ T cells following teriparatide treatment may account for its treatment effects on BRONJ. Some BRONJ model mice have been reported 35,36; however, we could not easily establish such model mice without using immunosuppressants, including cortical hormones. For this reason, in this study, we analyzed only wild type mice. However, BRONJ model mice should be studied in the near future if the model mice can be successfully established without immunosuppressants.

We believe that our study will provide some new information that will lead to an understanding of how teriparatide treatment affects BRONJ. Although the exact basis by which γδ T cells protect against BRONJ and a direct cause-effect relationship remains to be established, this study opens a new window into the potential importance of the immune-skeletal interface.

Conflicts of interest

The authors have no conflicts of interest relevant to this article.

Acknowledgements

This work was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (JSPS KAKEN Grant Number JP15K11246 to EY).

References

1. Berenson JR, Lipton A. Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med 1999;50:237–48.
2. Lipton A. Emerging role of bisphosphonates in the clinical–antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 2008;34:S25–30.
3. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer 1997;80:1652–60.
4. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095–105.
5. Ramaswamy B, Shapiro CL. Bisphosphonates in the prevention and treatment of bone metastases. Oncology 2003;17:1261–70.
6. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115–7.
7. Wimalawansa SJ. Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf 2008;7:491–512.
8. Patschan D, Loddenkemper K, Buttgerit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 2001;29:498–505.
9. Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med 2010;362:1005–13.
10. Kalyan S, Quabius ES, Wiltfang J, Monig H, Kabelitz D. Can peripheral blood gammadelta T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of aminobisphosphonate therapy. J Bone Miner Res 2013;28:728–35.
11. Kunzmann V, Bauer E, Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 1999;340:737–8.
12. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–41.
13. Faucheux C, Horton MA, Price JS. Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone. J Bone Miner Res 2002;17:455–64.
14. Saini V, Marengi DA, Barry KJ, et al. Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH. J Biol Chem 2013;288:20122–34.
15. Leupin O, Kramer I, Collette NM, et al. Control of the SOST mineralization process by PTH using MEF2 transcription factors. J Bone Miner Res 2007;22:1957–67.
16. Kramer I, Baertschi S, Halleux C, Keller H, Kneissel M. Mef2c deletion in osteocytes results in increased bone mass. J Bone Miner Res 2012;27:360–73.

17. Genetos DC, Toupadakis CA, Raheja LF, et al. Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J Cell Biochem 2010;110:457–67.

18. Collette NM, Genetos DC, Economides AN, et al. Targeted deletion of Sost distal enhancer increases bone formation and bone mass. Proc Natl Acad Sci U S A 2012;109:14092–7.

19. Drake MT, Srinivasan B, Modder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in post-menopausal women. J Clin Endocrinol Metab 2010;95:5056–62.

20. Piemonte S, Romagnoli E, Bratengeier C, et al. Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone. J Endocrinol Invest 2012;35:866–8.

21. Bedi B, Li JY, Tawfeek H, et al. Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH. Proc Natl Acad Sci U S A 2012;109:E725–33.

22. Terauchi M, Li JY, Bedi B, et al. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab 2009;10:229–40.

23. Li JY, Walker LD, Tyagi AM, Adams J, Weitzmann MN, Pacifici R. The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b. J Bone Miner Res 2014;29:43–54.

24. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007;65:573–80.

25. Yamachika E, Matsubara M, Ikeda A, Matsumura T, Moritani N, Iida S. Treatment of osteonecrosis of the jaw. J Craniomax Surg 2015;26:e575–7.

26. Yoshida D, Yamashita Y, Nakamichi I, et al. Weekly teriparatide injections successfully treated advanced bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int 2013;24:2365–9.

27. Onal M, Xiong J, Chen X, et al. Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem 2012;287:29851–60.

28. Tawfeek H, Bedi B, Li JY, et al. Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS One 2010;5:e12290.

29. Jarry CR, Duarte PM, Freitas FF, et al. Secreted osteoclastogenic factor of activated T cells (SOFAT), a novel osteoclast activator, in chronic periodontitis. Hum Immunol 2013;74:861–6.

30. Hartgring SA, Willis CR, Bijlsma JW, Lafeber FP, van Roon JA. Interleukin-7-aggravated joint inflammation and tissue destruction in collagen-induced arthritis is associated with T-cell and B-cell activation. Arthritis Res Ther 2012;14:R137.

31. Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci U S A 2003;100:125–30.

32. Pacifici R. Role of T cells in the modulation of PTH action: physiological and clinical significance. Endocrine 2013;44:576–82.

33. Tseng HC, Kanayama K, Kaur K, et al. Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation. Oncotarget 2015;6:20002–25.

34. Tipton DA, Seshul BA, Dabbous M. Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6. J Periodontal Res 2011;46:39–47.

35. de Molon RS, Cheong S, Bezuglaia O, et al. Spontaneous osteonecrosis of the jaws in the maxilla of mice on anti-resorptive treatment: a novel ONJ mouse model. Bone 2014;68:11–9.

36. Williams DW, Lee C, Kim T, et al. Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-kappaB ligand antibody in mice. Am J Pathol 2014;184:3084–93.